Shall we Sample Every Pancreatic Mass?Jean Louis Frossard*
Service of Gastroenterology and Hepatology, Geneva University Hospitals, Switzerland
- *Corresponding Author:
- Jean Louis Frossard
MD, Service of Gastroenterology and Hepatology
Geneva University Hospital
Rue Gabrielle-Perret-Gentil 4
1211 Genève, Switzerland
Tel: +41 22/372 93 46
Fax: +41 22/372 93 66
E-mail: [email protected]
Received Date: May 10, 2017; Accepted Date: June 12, 2017; Published Date: June 20, 2017
Citation: Frossard JL (2017) Shall we Sample Every Pancreatic Mass? J Cytol Histol 8: 453. doi: 10.4172/2157-7099.1000453
Copyright: © 2017 Frossard JL. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Sampling every pancreatic mass is debated but most observers believe that it should be mandatory for several reasons. Even if the vast majority of pancreatic masses consist of adenocarcinoma, 15% of them are of other origin and require their own specific therapy. Moreover, the progressive implementation of personalized medicine will allow offering the best therapeutic approach to any patient. Indeed, sampling any pancreatic mass can help determine the whole nature of the tumor (genomics, proteomics, and metabolomics) and thus permit to give the appropriate therapy only to patients that will certainly benefit from it.